Piramal Pharma Ltd management interview: Piramal Pharma Q2 Profit At ₹5 Crore After Year-Ago Loss; FY27 Growth Outlook Raised
Business Today, 2026-10-28. Video: https://www.youtube.com/watch?v=7E7oWI1R21k
- Revenue guidance: Raised FY27 revenue growth guidance to 19% to 20% after 28% second-quarter growth. First-half growth was 23%, with CDMO up 28%, CHG 24%, and Consumer Healthcare 14%.
- Differentiated products: Piramal said it is not really in GLP-1s, focusing instead on niche peptides and antibody-drug conjugates (ADCs), alongside sterile injectables. ADCs grew 51% over the last year.
- Capacity investments: A $60 million ADC expansion completed about 2 or 3 years ago, along with investments at Hemmo and Riverview, is beginning to deliver benefits; the company may consider further expansion.
- CDMO pipeline: The phase 3 pipeline has reached around 28 molecules, though about 1 in 2 phase 3 molecules fail in the clinic; some could reach commercial manufacturing within 1, 2, 3 years. Piramal cited its India, UK, and US footprint as a differentiator and is expanding sterile fill-finish capacity at Lexington.
- Profitability targets: EBITDA increased 72% from ₹385 crore, supported by fixed-cost leverage and increased US-site orders. The 2030 plan is $2 billion in revenue, $500 million in EBITDA, 25% EBITDA, and a 1 times debt-to-EBITDA ratio.